Abstract library

8 results for "Salgarello".
#885 The Role of Combined 68Ga-DOTATOC and 18F-FDG PET/CT in Patients with Pancreatic Neuroendocrine Tumors
Introduction: The value of combined (68)Ga-DOTATOC (68Ga) and (18)F-FDG (18FDG) PET/CT in diagnosis and staging of pancreatic NET is still unclear.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Stefano Partelli
#1198 Role of Combined 68Ga-DOTATOC and 18F-FDG PET-CT in the Diagnostic Workup of Well Differentiated Pancreas Neuroendocrine Tumors (PanNETs): A Surgical Series
Introduction: PanNETs have a broad spectrum of aggressiveness. Somatostatin-receptor based functional imaging, [68Ga]DOTATOC-PET/CT (GP), is recommended in the diagnostic workup of PanNETs; preliminary evidences show that [18F]FDG-PET/CT (FP) can provide prognostic information.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1383 [18F]FDG-PET/CT Heterogeneity in Patients with Metastatic, Well-Differentiated Pancreatic Neuroendocrine Tumours
Introduction: 18F-FDG-PET/CT (FP) often shows an heterogeneous pattern of positivity in patients (P) with pancreatic neuroendocrine tumours (PanNETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience
Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego
#1705 Prostate-Specific Membrane Antigen (PSMA) Uptake in a Pancreatic Neuroendocrine Tumor (pNET) Bearing Patient
Introduction: Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed on both prostate epithelial malignant cells and endothelial cells of tumor-associated neovasculature of many solid cancers. PSMA has been investigated already as a target in staging and detection of prostate cancer
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#1902 18F-FDG Positron Emission Tomography/Computed Tomography Positivity in Small Incidentally-Found Pancreatic Neuroendocrine Tumors: Could It Be Considered a Predictor of Malignancy?
Introduction: Surgical management of small (
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Doctor Anna Malpaga
#2241 Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and How?
Introduction: Pancreatic Neuroendocrine Tumors (pNETs) represent an increasing indication for pancreatic resection, but there are only few data about their possible recurrence after surgery.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Gaia Masini